The Pfizer-BioNTech Covid-19 Vaccine (BNT162b2) is based on the latter’s mRNA technology and authorised for emergency use in over 60 countries.
The latest data build upon and reinforce earlier evidence from the MOH showing the vaccine’s effectiveness in preventing symptomatic SARS-CoV-2 infections, Covid-19 cases, hospitalisations, severe and critical hospitalisations and deaths.
According to the latest information, protection is more robust two weeks after the second vaccine dose. Also, the vaccine showed at least 97% effectiveness in preventing symptomatic disease, severe and critical disease and death.
In addition, the analysis showed a 94% vaccine effectiveness against asymptomatic disease.
Pfizer noted that this real-world evidence could be important to all nations as they advance their inoculation campaigns a year after the World Health Organization (WHO) declared Covid-19 a pandemic.
MOH director professor Yeheskel Levy said: “Incidence rates in the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalised cases due to Covid-19.
“This clearly demonstrates the power of the Covid-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign.”
The findings were derived from de-identified aggregate Israel MOH surveillance data obtained between 17 January and 6 March.
During this time, the Pfizer-BioNTech vaccine was the only vaccine in the country and the highly infectious B.1.1.7 variant of SARS-CoV-2 (the UK variant) was the dominant strain.
Pfizer Vaccines senior vice-president and chief medical officer Luis Jodar said: “The findings, which suggest that the vaccine may also provide protection against asymptomatic SARS-CoV-2 infections, are particularly meaningful as we look to disrupt the spread of the virus around the globe.”